Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
June 2003
Features
Spotlight
Editorial Board Spotlight: Richard Afable, MD, MPH
P&T highlights the accomplishments of Dr. Afable, a board member since 2000.
Sonja Sherritze
Pediatric Drug Testing Update, United States
The FDA's mandate for improved pediatric labeling may lead to a much-needed increase in research for children's therapies.
Marvin M. Goldenberg, PhD, RPh, MS
Principles of Antibiotic Formulary Selection for P&T Committees: Overview
Burke A. Cunha, MD
Principles of Antibiotic Formulary Selection for P&T Committees: Overview -- Part 1: Antimicrobial Activity
First things first: antimicrobial agents should have a high degree of activity against the pathogens they are intended to treat.
Burke A. Cunha, MD
Continuing Education Credit
Incorporating Omalizumab into Asthma Treatment Guidelines: Consensus Panel Recommendations
A new drug, omalizumab (Xolair™), appears to be effective in overcoming the difficulties in treating persistent and moderate-to-severe asthma.
Lanny J. Rosenwasser, MD, FAAAAI, David B. Nash, MD, MBA, FACP, and members of the Consensus Panel
Departments
Editorial
Say It Ain’t So!
Editor-in-Chief David Nash, MD, MBA, discusses the dangers of violating drug-safety protocols in the name of “improved patient care."
David B. Nash, MD, MBA
Medication Errors
Limiting the Drug Inventory to Minimize Automated Dispensing Equipment Errors
Matthew Grissinger discusses how to reduce errors when using automated drug-dispensing cabinets.
Matthew Grissinger
Prescription Washington
Inspector General Cautions PBMs on Formulary Decision-Making
Stephen Barlas describes the Inspector General's guidelines for PBMs and P&T committees.
Stephen Barlas
Drug News
New Drugs/Drug News
P&T presents the latest information about approvals, indication changes, industry updates, and news from the FDA
Drug Forecast
Alefacept: A New Therapy for Psoriasis
The authors review alefacept (Amevive®) for the treatment of psoriasis.
Larisa Chagan, BS, PharmD
